Document Preview Unavailable

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Ana Liza Andresan Sun; Gillies, John David; Shen, Yang; Deng, Huajun; Xue, Fenchao; et al.  Clinical and Translational Science Vol. 17, Iss. 7,  (Jul 2024).

You might have access to this document